Catalyst Pharmaceuticals (CPRX) News Today

Mesirow Institutional Investment Management Inc. raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 29.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 934,234 shares of the biopharm

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Zacks Research increased their Q3 2024 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a research report issued on Wednesday, August 28th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutic

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now directly owns 348,874 shares in the company, valued at $7,012,367.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Down 2.1% Following Insider Selling

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) insider Steve Miller sold 150,000 shares of the company's stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the transaction, the insider now directly owns 675,124 shares of the company's stock, valued at $13,738,773.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 12-Month High at $20.81

Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 2.7% Higher

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) saw a significant drop in short interest during the month of July. As of July 31st, there was short interest totalling 4,820,000 shares, a drop of 9.9% from the July 15th total of 5,350,000 shares. Currently, 4.7% of the shares of the company are sold short. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is presently 4.4 days.

Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 1-Year High at $19.87

HC Wainwright upped their price objective on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a "buy" rating in a report on Monday.

StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday.

Citigroup lifted their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a research report on Friday.

Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 1-Year High Following Analyst Upgrade

Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Up 8.4%

DekaBank Deutsche Girozentrale bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 171,376 shares of the biopharmaceutical c

Boston Partners lessened its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 2.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 1,506,930 shares of the biopharmaceutical company's stock after selling 34,730 shares during the

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the five analysts that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The avera

Vanguard Group Inc. grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 12.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 7,980,661 shares of the biopharmaceutical company's stock after acquiring an additional 860,2

Jacobs Levy Equity Management Inc. lessened its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 2.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,255,880 shares of the biopharmaceutical c

Catalyst Pharmaceuticals (NASDAQ:CPRX) will be releasing earnings after the market closes on Wednesday, August 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=610962)

Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 12-Month High at $17.99

Sei Investments Co. boosted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 64.3% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 83,360 shares of the biopharmaceutical company's stock after acq

Russell Investments Group Ltd. lifted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 23.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 237,744 shares of the biopharmaceutical comp

Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 1-Year High at $17.72

Jupiter Asset Management Ltd. decreased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 4.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 809,360 shares of the biopharmaceutical com

BNP Paribas Financial Markets lowered its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 69.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 89,967 shares of the biophar

Oppenheimer & Co. Inc. bought a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 50,531 shares of the biopharmaceutical company's stock, valu

LSV Asset Management lowered its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 27.2% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 896,000 shares of the biopharmaceutical company's stock after sell

GSA Capital Partners LLP purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 59,838 shares of the biopharmaceutical compa

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have earned a consensus recommendation of "Buy" from the five ratings firms that are covering the stock, Marketbeat reports. Five research analysts have rated the stock with a buy rating. The average 1 year price objective am

Vanguard Group Inc. increased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 1.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,120,417 shares of the bi

Catalyst Pharmaceuticals (NASDAQ:CPRX) will be releasing earnings before the market opens on Friday, July 5, Yahoo Finance reports.

Juncture Wealth Strategies LLC grew its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 764.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 94,583 shares of the biopharmaceutical company's